1 Global variation in tests of cognitive and physical function: analysis of six

2 international randomized controlled trials

- 3
- 4 Aristeidis H. Katsanos, MD, PhD*^{1,2}; Shun Fu Lee, PhD*¹; Tali Cukierman-Yaffe,
- 5 MD, MSc^{3,4}; Laura Sherlock, MSc⁵; Graciela Muniz-Terrera, PhD⁶; Michele
- 6 Canavan, MD^{7,8}; Raed Joundi, MD, PhD^{1,2}; Mukul Sharma, MD, MSc^{1,2}; Ashkan
- 7 Shoamanesh, MD^{1,2}; Andrea Derix, PhD⁹; Hertzel C. Gerstein, MD^{1,10}; Salim Yusuf,
- 8 MD, PhD^{1,11}; Martin J. O'Donnell, MD^{7,8}; Jackie Bosch, PhD*^{1,12}; William N.
- 9 Whiteley, $MD^{*1,5,13}$
- 10
- 11 *equal author contribution
- 12
- 13 <u>Affiliations</u>
- ¹⁴ ¹*Population Health Research Institute, Hamilton, ON, Canada*
- ²Department of Medicine (Neurology), McMaster University, Hamilton, ON, Canada
- ³Department of Epidemiology and Preventive Medicine, Sackler Faculty of Medicine,
- 17 School of Public Health, Tel Aviv University, Herczeg Institute on Aging, Tel Aviv,
- 18 Israel
- ⁴Division of Endocrinology & Metabolism, Sheba Medical Centre, Tel Hashomer,
- 20 Ramat Gan, Israel
- ⁵*Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK*
- ⁶Edinburgh Dementia Prevention, Centre for Clinical Brain Sciences, University of
- 23 Edinburgh, Edinburgh, UK
- ²⁴ ⁷*HRB-Clinical Research Facility, National University of Ireland, Galway, Ireland*
- 25 ⁸Department of Geriatric and Stroke Medicine, Galway University Hospital,
- 26 Newcastle Road, Ireland

- ⁹*Global Program Head Thrombosis, Bayer Pharmaceuticals, Germany*
- 28 ¹⁰Hamilton Health Sciences, Hamilton, ON, Canada
- 29 ¹¹Department of Medicine (Cardiology), McMaster University, Hamilton, ON,
- 30 *Canada*
- 31 ¹²School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada
- ¹³*Nuffield Department of Population Health, University of Oxford*
- 33
- 34 <u>Corresponding author</u>:
- 35 Dr. Aristeidis H. Katsanos, MD, PhD
- 36 Division of Neurology, McMaster University & Population Health Research Institute,
- 37 Hamilton, ON, Canada
- 38 E-mail: <u>ar.katsanos@gmail.com</u>
- 39 Tel: +1-365-888-1441; Fax: +1-905-296-5806
- 40
- 41 *Number of tables:* 0
- 42 *Number of supplemental tables:* 5
- 43 Number of figures: 4
- 44 Number of color figures: 4
- 45 *Number of supplemental figures:* 1
- 46 *Number of references: 38*
- 47 Word count of abstract: 250

48 Total word count of text: 2705

49 *Keywords:* cognition; dementia; function; country; cardiovascular

50 **Impact statement**

We certify that this work is novel. After analysing data from a large cohort of participants with a history of cardiovascular disease or cardiovascular risk factors, who were recruited in six international randomised controlled trials (RCTs) we found that accounting for country-level factors reduced large differences between world regions in estimates of cognitive impairment, while measures of functional impairment were less variable across world regions.

57

58 Key Points

- Cognitive and functional test scores in randomized controlled clinical trial
 cohorts vary widely across world regions.
- The difference in cognitive test performance was large in comparison to
 difference in measures of activities of daily living (ADLs). Accounting for
 country-level factors reduced the differences between world regions in
 estimates of cognitive impairment.
- Cognitive test measures were less variable and could be used to better estimate
 dementia incidence in international studies.
- 67

68 Why this study matters?

We found that cognitive and functional test scores in RCT cohorts varied widely across world regions. The difference in cognitive test performance was large in comparison to difference in measures of activities of daily living. The impact of differences on the performance of cognitive tests, which were developed in high-

73	income countries, creates challenges for harmonized studies of cognitive decline
74	prevention in different world regions. Future studies using the same test around the
75	world could standardise cognitive score by country, and consider using in addition
76	measures of instrumental and basic activities of daily living, where there is less
77	variation across world regions.
78	
79	Acknowledgments section
80	
81	Conflict of Interest
82	Authors report no conflicts of interest relevant to this particular manuscript
83	
84	Author Contributions
85	AHK, SFL, JB, WNW constructed the study design and prepared the first draft of the
86	manuscript. SFL performed the statistical analyses and prepared the figures. All other
87	authors revised the first manuscript draft for important intellectual content.
88	
89	Sponsor's Role
90	The sponsor had no involvement in the study design, manuscript preparation or
91	decision for publication.
92	
93	
94	
95	
96	
97	

98

- 99
- 100
- 101 Abstract

<u>Background:</u> Better understanding of global variation in simple tests of cognition and
 function would aid the delivery and interpretation of multi-national studies of the
 prevention of dementia and functional decline.

105 Methods: We aim to describe the variation in simple measures of cognition and 106 function by world region, study, recruitment centre or individual level factors. In six 107 RCTs that measured cognition with the mini-mental state examination (MMSE), 108 Montreal cognitive assessment (MoCA), and instrumental activities of daily living 109 (IADL) with the Standardised Assessment of Everyday Global Activities (SAGEA), 110 we estimated average scores by global region with multilevel mixed-effects models. 111 We estimated the proportion of participants with cognitive or functional impairment 112 with previously defined thresholds (MMSE \leq 24 or MoCA \leq 25, SAGEA \geq 7), and with a 113 country-standardised z-score threshold of cognitive or functional score of \leq -1.

114 Results: In 91,396 participants (mean age 66.6 ± 7.8 years, 31% females) from seven 115 world regions, all global regions differed significantly in estimated cognitive function 116 (z-score differences 0.11–0.45, p<0.001) after accounting for individual-level factors, 117 centre and study. In different regions, the proportion of trial participants with 118 MMSE \leq 24 or MoCA \leq 25 ranged from 23–36%; the proportion below a country-119 standardised z-score threshold of ≤ 1 ranged from 10–14%. The differences in 120 prevalence of impaired IADL (SAGEA≥7) ranged from 2–6% and by country-121 standardised thresholds from 3-6%.

<u>Conclusions:</u> Accounting for country-level factors reduced large differences between
world regions in estimates of cognitive impairment. Measures of IADL were less
variable across world regions, and could be used to better estimate dementia incidence
in large studies.

126 Introduction

Although international studies of cardiovascular disease prevention usually measure the incidence of major adverse cardiovascular events, they rarely measure functional impairments, such as cognition or the ability to perform everyday activities.^{1, 2} Although they are important to people, these measures of function are hard to measure and standardize internationally. International standardization of measures of function would be needed for drug approval in each country,³ although there are no generally agreed measures.

134 Culturally appropriate assessments designed to measure cognition or function in individual countries or regions could have internal consistency,⁴ but they are 135 136 difficult to use at scale or to aggregate between regions. Therefore, using the same 137 assessment tools in all countries is preferable, but requires researchers to recognize 138 and address sources of variation in measuring test performance such as educational 139 attainment, familiarity with testing instruments and the applicability of the functional activities assessed to different regions.^{5, 6} A better understanding of global variation in 140 141 similar tests of cognition and function, and the sources of variation, would improve 142 measurement, analysis, and interpretation of the results of multi-national studies of 143 cognitive and functional impairment.

We used data from a large cohort of participants with a history of cardiovascular disease or cardiovascular risk factors, in six international randomised controlled trials (RCTs) that assessed antihypertensive, antidiabetic and

147 antithrombotic medications, to describe the variation in simple measures of cognition 148 and function (activities of daily living) by world region. We then sought to determine 149 if variation in the results of cognitive and functional tests between world regions 150 could be explained by study, recruitment centre or individual level factors. We 151 calculated the prevalence of significant cognitive or functional impairment in different 152 world regions, using widely accepted thresholds for cognitive or functional tests, and 153 explored whether country-standardization changed the differences in these estimates 154 between world regions.

155

156 Methods

157 *Population*

158 We included participants from six large international cardiovascular prevention RCTs.⁷⁻¹² Ongoing Telmisartan Alone and in Combination with Ramipril 159 160 Global Endpoint Trial (ONTARGET) randomly allocated 25,620 participants with 161 coronary artery disease, peripheral artery disease, cerebrovascular disease, or diabetes mellitus with end-organ damage to ramipril (10 mg once daily), telmisartan (80 mg 162 once daily), or a combination of both.⁷ Telmisartan Randomised AssessmeNt Study in 163 164 ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) randomly 165 allocated 5,926 participants meeting the ONTARGET inclusion criteria but intolerant to ACE inhibitors to either telmisartan (80 mg once daily) or placebo.⁸ Outcome 166 167 Reduction with an Initial Glargine Intervention (ORIGIN) randomly allocated 12,537 168 participants over the age of 50 with cardiovascular risk factors plus impaired fasting 169 glucose, impaired glucose tolerance, or type 2 diabetes to receive insulin glargine 170 (with a target fasting blood glucose level of 95 mg or less per deciliter [5.3 mmol per 171 liter]) or standard care and to receive n-3 fatty acids or placebo using a 2-by-2

172	factorial design. ⁹ The Cardiovascular Outcomes for People Using Anticoagulation
173	Strategies (COMPASS) trial randomly allocated 27,395 participants with stable
174	atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus
175	aspirin (100 mg once daily), rivaroxaban (5 mg twice daily) monotherapy, or aspirin
176	monotherapy (100 mg once daily). ¹⁰ New Approach Rivaroxaban Inhibition of Factor
177	Xa in a Global Trial versus ASA to Prevent Embolism in Embolic Stroke of
178	Undetermined Source (NAVIGATE ESUS) randomly allocated 7,213 participants
179	with a recent embolic stroke of presumed cardioembolic source to either rivaroxaban
180	(15 mg once daily) or aspirin (100 mg once daily). ¹¹ The Heart Outcomes Prevention
181	Evaluation (HOPE)-3 trial randomly allocated 12,705 participants with intermediate
182	cardiovascular disease risk to receive rosuvastatin (10 mg once daily) or placebo and
183	to receive a combination of candesartan/ hydrochlorothiazide (16/12.5 mg once daily)
184	or placebo, using a 2-by-2 factorial design. ¹² In HOPE-3 cognitive assessments were
185	obtained only for those 70 years and older. ¹²

186 *Exposures*

We grouped countries into seven world regions: North America, Oceania and
Western Europe; South America; Eastern Europe and Russia; East Asia; South Asia;
Africa; and West Asia (Supplementary Table 1).¹³

Individual participant covariates, measured as continuous variables at either the run-in or randomization visit, were: age in years, body mass index (BMI), waist circumference; systolic and diastolic blood pressure; fasting glucose; and hemoglobin A1c % measured in Diabetes Control and Complications Trial (DCCT) units. We included the following binary variables (yes versus no, excluding missing or unknown) assessed at either the run-in or randomization visit: sex; regular alcohol use (drinking alcohol once or more per week); employment; history of coronary or

197 cerebrovascular disease (transient ischemic attack, stroke, myocardial infarction, 198 angina, heart failure), atrial fibrillation, peripheral arterial disease, hyperlipidemia, 199 hypertension, diabetes mellitus, other non-vascular co-morbidities (cancer, renal 200 dysfunction, liver disease, depression) and history of fall or fracture. Education was 201 categorized as: none or less than primary, primary or secondary, or trade 202 school/college/university. We used the components of the EQ-5D assessment in each 203 trial to derive information on depression and disability.¹⁴

204 *Outcomes*

205 For different world regions we presented the results of a cognitive assessment at 206 either the run-in or randomization visit, which was performed using two cognitive 207 tests: the Mini-Mental State Examination (MMSE), a 30-point assessment that 208 addresses seven different cognitive domains (range 0-30, with higher scores meaning better cognition)¹⁵ and the Montreal Cognitive Assessment (MoCA), a 30-point 209 210 assessment that addresses seven different cognitive domains (range 0-30, with higher 211 scores meaning better cognition). For the MoCA test an additional point is granted to 212 individuals with 12 or fewer years of education. The MMSE was performed in the ORIGIN, TRANSCEND and ONTARGET trials,⁷⁻⁹ while MoCA was performed in 213 HOPE-3, COMPASS and NAVIGATE ESUS.¹⁰⁻¹² The short version of the MoCA 214 215 test (maximum score of 12) was completed in HOPE-3, and in our analyses was normalized it to a 30-point scale to allow comparison with other studies.^{16, 17} In a 216 217 subset of trials, we measured the Standardised Assessment of Everyday Global 218 Activities (SAGEA), a 15-item patient-reported outcome measure developed to 219 measure functional status (basic, instrumental, and cognitive activities of daily living) 220 in patients with vascular disease (range 0-45, with higher scores denoting worse

function).¹⁸ The individual items and scoring for the SAGEA is outlined in the
Appendix. All tests were administered in the language of participants.

223 *Statistical analysis*

224 Participants with cognitive or functional assessment available either at run-in 225 or randomization visits were included in the analyses. To account for differences in 226 the study populations we standardised cognitive and functional test scores to the 227 population of each study (study-standardised) or the country's population (country-228 standardised). Each participant's raw score was subtracted from the study's or 229 country's specific mean score, and the difference was then divided by the study's or 230 country's specific baseline standard deviation (SD), respectively. Given the 231 comparability in z-scores by age between MMSE and MoCA (Supplementary Figure 232 1), ¹⁹ we pooled the standardised z-scores of these two tests.

233 We then constructed multilevel mixed-effects models using the study-234 standardised or country-standardised test scores as the dependent variable, the 235 baseline participant covariates as fixed-effects modifiers and the recruiting centre as a 236 random-effects modifier (allowing testing of between centre heterogeneity). In the 237 unadjusted model we provide the crude estimates; in the age-sex-adjusted model we 238 adjust only for the individual's age and sex and in the maximally-adjusted model we adjust for the individual's age, sex, education, BMI, history of cardiovascular disease, 239 240 history of cardiovascular risk factors, history of non-cardiovascular diseases and 241 baseline blood pressure. We used the North America, Oceania and Western Europe 242 group as reference, since cognitive and functional tests were developed in countries 243 from these geographical regions, and present the unadjusted and adjusted mean 244 differences and corresponding 95% confidence intervals (95%CI) for other world 245 regions.

246 We estimated the prevalence of cognitive impairment in different world 247 regions with absolute score thresholds for the MMSE (≤ 24 points) or MoCA (≤ 25 points).^{20, 21} and with a threshold for the study- and country-standardised scores that 248 249 corresponds to the thresholds of MMSE (24 points or less) or MoCA (25 points or less) in the North America, Oceania and Western Europe group $(z \le 1.0)$.²² We then 250 251 applied this z-score threshold to the other world regions. The same approach was used 252 to estimate the prevalence of functional impairment in different world regions with the absolute threshold of 7 or more points in the SAGEA score,¹⁸ and then applied the 253 254 respective z-score threshold for a score of 7 to study- or country-standardised 255 distributions from the other world regions. We calculated the intraclass correlation 256 coefficient (ICC), the proportion of variation within clusters (world regions) over the 257 total variation, for each analysis to estimate the variation of cognitive or functional 258 impairment between the different world regions. The chi-square test was used to test 259 the homogeneity of intraclass correlations.

260 Standard Protocol Approvals, Registrations, and Patient Consents

The present work is a post-hoc analysis of previously published randomized controlled clinical trials coordinated by the Population Health Research Institute and was exempt from ethics review board approval. For the collection of data in original studies, informed consent was obtained by primary investigators.

265 **Results**

We analyzed data from 91,396 participants in six RCTs from 55 countries recruited between 2001 and 2017 in seven world regions (Supplementary Table 1): North America, Oceania, and Western Europe (39,668); South America (17,923); Eastern Europe and Russia (13,433); East Asia (11,667); South Asia (5,146); Africa (2,273) and West Asia (1,286). Participants had a mean age of 66.6 years (SD 7.8),

271 and 31% were females. Few participants were smokers (17%) or regularly used 272 alcohol (25%). Most participants were educated to primary or secondary level (54%), 273 39% to higher technical level and 3% had no or less than primary education. Almost a 274 third of participants were employed at study enrolment, 18% had self-reported 275 depression and 9% had self-reported disability based on the EQ-5D questionnaire 276 assessment. More than 90% of the participants had at least one cardiovascular risk 277 factor and 69% had a history of one or more cardiovascular diseases (Supplementary 278 Table 2). Additional participant and country characteristics are provided in 279 Supplementary Table 3.

Participants' baseline characteristics demonstrating the greatest variability included alcohol consumption (ranging from 12% in South Asia to 30% in North America, Oceania and Western Europe), self-reported depression (ranging from 12% in Africa to 24% in South America) and self-reported disability (ranging from 3% in East Asia to 18% in South Asia). The prevalence of cardiovascular disease comorbidity at baseline study assessment also varied between the different world regions (Supplementary Table 2).

Study-standardised cognitive test scores were lower in people who were older in all world regions except Africa, with large differences between regions (Figure 1A). However, when cognitive scores were standardised to country, older people had consistently lower cognitive scores in all regions, and the variation in z-scores between regions was attenuated (Figure 1B).

292 Cognitive test z-scores standardised for study (adjusted for individual 293 characteristics and centre from which they were recruited), were significantly lower in 294 world regions (p<0.001 for all regions) compared with North America, Oceania and 295 Western Europe (greatest difference for South America z-score mean difference -0.45

[95% CI: -0.51 to -0.40]). Standardizing the cognitive test scores for country
(adjusting for individual characteristics and centre) reduced variation between world
regions. South America, Eastern Europe and Russia, East Asia, Africa and West Asia
had modest differences (all z-score mean difference >-0.1, p>0.05) from North
America, Oceania and Western Europe, although the difference was slightly greater
for South Asia (z-score mean difference: -0.12, 95%CI: -0.22 to -0.02; Figure 2,
Supplementary Table 4).

303 Widely used absolute thresholds for MMSE (≤ 24 points) or MOCA (≤ 25 304 points) classified 27% of the overall population with cognitive impairment, with 305 proportions ranging from 23% in North America, Oceania and Western Europe to 306 36% in South America and West Asia (ICC=0.032, χ^2 =1787). Using the 307 corresponding absolute values z-score threshold of -1.0 (Supplementary Table 5) in 308 study-standardised (not shown) and country standardized cognitive scores led to a 309 lower proportion of participants in each region classified with cognitive impairment 310 (Figure 3).

311 The study-standardized functional SAGEA scores (adjusted for individual 312 characteristics and centre) were lower in Africa (z-score mean difference: -0.32, 313 95%CI: -0.59 to -0.05) and West Asia (-0.41, 95%CI: -0.63 to -0.19), and higher in 314 East Asia (+0.23, 95% CI: 0.15 to 0.32) compared with North America, Oceania and 315 Western Europe. However, after country standardization (and adjusting for individual 316 characteristics and centre), there were no large or significant differences in SAGEA 317 scores between world regions (all z-score mean differences ≤ 0.18 , p>0.05; Figure 2 & 318 Supplementary Table 4).

With a threshold ≥7 points in SAGEA score, 4% of the population was
classified with functional impairment, with prevalence rates between regions from 2

to 7% (ICC=0.028, χ^2 =89). A z-score of -1.0 in study-standardised distributions and country-standardised distributions resulted in 3% (range 2-6%, ICC=0.024, χ^2 =191) and 4% (range 2-4%, ICC=0.0007, χ^2 =41) prevalence rates of functional impairment, respectively (Figure 4).

325 Discussion

We found that cognitive and functional test scores in RCT cohorts varied widely across world regions. The difference in cognitive test performance was large in comparison to difference in measures of activities of daily living.

329 These differences in cognitive test scores attenuated modestly after adjusting 330 for individual level factors, or randomisation centre, a surrogate for the socio-331 economic status of the area. However, when standardising for country, the differences 332 attenuated substantially, suggesting that unmeasured country-level factors accounted 333 for much of the difference in test performance. Better measurement of educational 334 experience and literacy could further reduce differences in cognitive test performance. 335 Our results are in accordance with previous literature suggesting that there is substantial variation in cognitive test performance between different world regions.^{4, 6,} 336 ¹³ The variability in cognitive test performance between different world regions has 337 338 previously been associated with modifiable and non-modifiable individual-level factors,²³⁻²⁷ and the socio-economic status of the area of residence for an individual.²⁸⁻ 339 31 340

The prevalence of cognitive impairment using widely accepted absolute cognitive score thresholds was very large, suggesting factors related to test performance rather than cognitive impairment were responsible for these differences and questioning the suitability of these thresholds for population-based studies. This problem has been identified previously in population-based studies.³² In Sweden, a

MoCA threshold of 25 points or less classified 37.3% of the population as cognitively impaired.³³ A systematic review and meta-analysis of the cross-cultural applicability of MoCA screening for mild cognitive impairment found a wide range of suggested cut-offs both across countries and within regions.³⁴ For example, the cut-off scores of the MoCA were different for five Chinese versions, ranging between 23 and 25 for mild cognitive impairment and between 19 and 24 for dementia.³⁵

In our study, functional measurement showed less variation by region and demonstrate that the use of measures of activities of daily living along with cognitive scores could be used to support a diagnosis of significant cognitive impairment in international studies. Functional measures showed much less regional variation in scores than measures of cognition even before taking into account individual, centres or country-level factors. Tests that use functional measures to measure impairment, although less sensitive might be more consistent between world regions.

359 Our study had a number of limitations. We analyzed cognitive and functional 360 assessment scores from participants recruited in international large-scale RCTs of 361 cardiovascular interventions. Although these trials were performed in multiple 362 countries and centres around the world, resulting in a multi-ethnic and culturally 363 diverse population, these participants were not representative of their country 364 populations, and our findings are only relevant for trials population. Individuals who 365 agree to participate in RCTs can be very different from the general population on 366 factors beyond the overt inclusion/exclusion criteria. There were substantial 367 differences in the total number of individuals from each of the world regions, leading 368 to increased uncertainty and less precise fit of statistical models for the regions with 369 fewest participants (i.e. West Asia, Africa). Additionally, the number of countries 370 included in each world region differed, e.g. only one country was included for Africa

group and 20 countries were included for North America, Oceania and Western
Europe group (Supplementary Table 1). Finally, there was no clinical diagnosis of
dementia or mild cognitive impairment, although all patients were able to consent,
and none had recorded dementia at baseline.³⁶

375 The impact of differences on the performance of cognitive tests, which were 376 developed in high-income countries, creates challenges for harmonized studies of cognitive decline prevention in different world regions.³⁷ Universal cut-offs for 377 378 cognitive decline may lead to erroneous conclusions about an individual's cognitive 379 ability and pose barriers in the interpretation and collation of the results from these tests in international studies.³⁸ New tests could be developed for each country, 380 381 although this increases study cost and complexity. Future studies using the same test 382 around the world could standardise cognitive score by country, and consider using in 383 addition measures of instrumental and basic activities of daily living, where there is 384 less variation across world regions.

385

386 **References**

387	1. Iadecola C, Yaffe K, Biller J, et al; American Heart Association Council on
388	Hypertension; Council on Clinical Cardiology; Council on Cardiovascular Disease in
389	the Young; Council on Cardiovascular and Stroke Nursing; Council on Quality of
390	Care and Outcomes Research; and Stroke Council. Impact of hypertension on
391	cognitive function: a scientific statement from the American Heart Association.
392	Hypertension. 2016;68:e67-e94.
393	2. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the
394	efficacy and safety of statin therapy. Lancet. 2016;388:2532-2561.
395	3. Katz R. FDA: evidentiary standards for drug development and approval. NeuroRx.
396	2004;1:307-16.
397	4. Prince M, Acosta D, Chiu H, Scazufca M, Varghese M; 10/66 Dementia Research
398	Group. Dementia diagnosis in developing countries: a cross-cultural validation study.
399	Lancet. 2003;361:909-17.
400	5. Max Roser and Esteban Ortiz-Ospina (2016) - "Literacy". Published online at
401	OurWorldInData.org. Retrieved from: 'https://ourworldindata.org/literacy' [Online
402	Resource]
403	6. Ng KP, Chiew HJ, Lim L, Rosa-Neto P, Kandiah N, Gauthier S. The influence of
404	language and culture on cognitive assessment tools in the diagnosis of early cognitive
405	impairment and dementia. Expert Rev Neurother. 2018;18:859-869.
406	7. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril,
407	or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59.
408	8. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with
409	cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C,
410	et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events

411	in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a
412	randomised controlled trial. Lancet. 2008;372:1174-83.
413	9. ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, et al. Basal
414	insulin and cardiovascular and other outcomes in dysglycemia. Basal insulin and
415	cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319-328.
416	10. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin
417	in stable cardiovascular disease. N Engl J Med. 2017;377:1319-1330.
418	11. Hart RG, Sharma M, Mundl H, et al. Rivaroxaban for Stroke Prevention after
419	Embolic Stroke of Undetermined Source. N Engl J Med. 2018;378:2191-2201.
420	12. Yusuf S, Lonn E, Pais P, et al. Blood-Pressure and Cholesterol Lowering in
421	Persons without Cardiovascular Disease. N Engl J Med. 2016;374:2032-2043.
422	13. Kalaria RN, Maestre GE, Arizaga R, et al. Alzheimer's disease and vascular
423	dementia in developing countries: prevalence, management, and risk factors. Lancet
424	Neurol. 2008;7:812-26.
425	14. EuroQol Group. EuroQola new facility for the measurement of health-related
426	quality of life. Health Policy. 1990;16:199-208.
427	15. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method
428	for grading the cognitive state of patients for the clinician. J Psychiatr Res.
429	1975;12:189-98.
430	16. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive
431	Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am
432	Geriatr Soc. 2005;53:695-9.
433	17. Dong Y, Koay WI, Yeo LL, Chen CL, Xu J, Seet RC, Lim EC. Rapid Screening

434 for Cognitive Impairment in Parkinson's Disease: A Pilot Study. Parkinsons Dis.
435 2015;2015:348063.

- 436 18. Spence J, Bosch J, Chongsi E, et al. Standardized Assessment of Global activities
- 437 in the Elderly scale in adult cardiac surgery patients. Br J Anaesth. 2021;127:539-546.
- 438 19. Yang H, Yim D, Park MH. Converting from the Montreal Cognitive Assessment
- to the Mini-Mental State Examination-2. PLoS One. 2021;16:e0254055.
- 440 20. Creavin ST, Wisniewski S, Noel-Storr AH, et al. Mini-Mental State Examination
- 441 (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and
- 442 over in community and primary care populations. Cochrane Database Syst Rev.443 2016:CD011145.
- 444 21. Davis DH, Creavin ST, Yip JL, Noel-Storr AH, Brayne C, Cullum S. Montreal
- 445 Cognitive Assessment for the detection of dementia. Cochrane Database Syst Rev.
- 446 2021;7:CD010775.
- 447 22. Perkins NJ, Schisterman EF. The inconsistency of "optimal" cutpoints obtained
- using two criteria based on the receiver operating characteristic curve. Am JEpidemiol. 2006;163:670-5.
- 450 23. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention,
- and care: 2020 report of the Lancet Commission. Lancet. 2020;396:413-446.
- 452 24. Daviglus ML, Bell CC, Berrettini W, et al. National Institutes of Health State-of-
- the-Science Conference statement: preventing alzheimer disease and cognitivedecline. Ann Intern Med. 2010;153:176-81.
- 455 25. Kivimäki M, Singh-Manoux A, Pentti J, et al. Physical inactivity, cardiometabolic
 456 disease, and risk of dementia: an individual-participant meta-analysis. BMJ.
 457 2019;365:11495.
- 458 26. Albanese E, Lombardo FL, Prince MJ, Stewart R. Dementia and lower blood
 459 pressure in Latin America, India, and China: a 10/66 cross-cohort study. Neurology.
 460 2013;81:228-35.

- 461 27. Ott A, Breteler MM, van Harskamp F, et al. Prevalence of Alzheimer's disease
 462 and vascular dementia: association with education. The Rotterdam study. BMJ.
 463 1995;310:970-3.
- 464 28. Selvamani Y, Arokiasamy P. Association of life course socioeconomic status and465 adult height with cognitive functioning of older adults in India and China. BMC
- 466 Geriatr. 2021;21:354.
- 467 29. Yu X, Zhang W, Kobayashi LC. Duration of Poverty and Subsequent Cognitive
- 468 Function and Decline Among Older Adults in China, 2005-2018. Neurology.
 469 2021;97:e739-e746.
- 470 30. Paradela RS, Ferreira NV, Nucci MP, et al. Relation of a Socioeconomic Index
- 471 with Cognitive Function and Neuroimaging in Hypertensive Individuals. J Alzheimers
- 472 Dis. 2021;82:815-826.
- 473 31. Okamoto S. Socioeconomic factors and the risk of cognitive decline among the
 474 elderly population in Japan. Int J Geriatr Psychiatry. 2019;34:265-271
- 475 32. Borland E, Nägga K, Nilsson PM, Minthon L, Nilsson ED, Palmqvist S. The
- 476 Montreal Cognitive Assessment: Normative Data from a Large Swedish Population-
- 477 Based Cohort. J Alzheimers Dis. 2017;59:893-901.
- 478 33. Chandra V, Ganguli M, Ratcliff G, et al. Studies of the epidemiology of dementia:
- 479 comparisons between developed and developing countries. Aging Milano 1994; 6:480 307–21.
- 481 34. O'Driscoll C, Shaikh M. Cross-Cultural Applicability of the Montreal Cognitive
- 482 Assessment (MoCA): A Systematic Review. J Alzheimers Dis. 2017;58:789-801.
- 483 35. Tan JP, Li N, Gao J, et al. Optimal cutoff scores for dementia and mild cognitive
- 484 impairment of the Montreal Cognitive Assessment among elderly and oldest-old
- 485 Chinese population. J Alzheimers Dis. 2015;43:1403-12.

486	36. Llibre Rodriguez JJ, Ferri CP, Acosta D, et al. Prevalence of dementia in Latin
487	America, India, and China: a population-based cross-sectional survey. Lancet.
488	2008;372:464-474.
489	37. Magklara E, Stephan BCM, Robinson L. Current approaches to dementia
490	screening and case finding in low- and middle-income countries: Research update and
491	recommendations. Int J Geriatr Psychiatry. 2019;34:3-7.
492	38. Whiteley WN, Anand S, Bangdiwala SI, et al. Are large simple trials for dementia
493	prevention possible? Age Ageing. 2020;49:154-160.
494	
495	
496	

497

Figure 1. Fitting splines on the association between individual's age and (A) study-standardised or (B) country-standardised cognitive scores by different world regions. Box plot illustrate the median, interquartile range and range of scores in the whole study population.

(STD: standardised; NA: North America; SA: South America; EE: Eastern Europe; EAsia: East Asia; SAsia: South Asia; W.Asia: West Asia)

Figure 2. Mean differences in study-standardised or country-standardised baseline cognitive and functional test scores between the North America, Oceania and Western Europe group and other world regions, adjusted for individual participant characteristics and centre of recruitment.

(SAGEA: Standardised Assessment of Global activities in the Elderly; NA: North America; SA: South America; EE: Eastern Europe; EAsia: East Asia; SAsia: South Asia; W.Asia: West Asia)

Figure 3. Estimated prevalence of cognitive impairment in different word regions using absolute $(MMSE \le 24)$ or $MOCA \le 25)$ or relative thresholds (z-score ≤ -1.0) based on the study-standardised or country-standardised mean cognitive test scores. Intraclass correlation coefficient (ICC) is the proportion variance within clusters over the total variance. (NA: North America; SA: South America; EE: Eastern Europe; EAsia: East Asia; SAsia: South Asia; W.Asia: West Asia)

Figure 4. Estimated prevalence of functional impairment in different word regions using absolute (SAGE \geq 7) or relative thresholds (z-score \leq -1.0) based on the study-standardised or country-standardised mean functional test scores. Intraclass correlation coefficient (ICC) is the proportion variance within clusters over the total variance. (NA: North America; SA: South America; EE: Eastern Europe; EAsia: East Asia; SAsia: South Asia; W.Asia: West Asia)







Baseline Cognitive Score

Study standardized Country standardized



Baseline SAGEA Score





